Selected Collaboration Highlights
May 2026 — Inbrija® Licensing-In Collaboration
- Coalescence BioPharma's founder supported strategic business development activities, including scientific assessment and partner engagement, that contributed to the exclusive licensing of INBRIJA® in mainland China, Hong Kong, and Macao.
- Read the Official Collaboration Announcement
May 2025 — Bijuva® Licensing-In Collaboration
- Coalescence BioPharma's founder supported opportunity identification, scientific evaluation, and partner engagement that contributed to the licensing and distribution agreement between Theramex and Jincheng Pharmaceutical for mainland China, Hong Kong, and Macao.
- Read the Official Collaboration Announcement
The following examples reflect selected therapeutic programs previously evaluated or supported through scientific assessment, global positioning, and business development activities.
| Therapeutic Focus | Modality | Stage at Time of Engagement | Scope of Support |
|---|---|---|---|
| Metabolic / MASH | Biologic | Clinical-stage | Scientific assessment and global positioningScientific assessment and global positioning |
| Immunology / CKD-associated anemia | Monoclonal antibody | Clinical-stage | Scientific evaluation and partnering strategy |
| Pulmonary fibrosis | Small molecule | Clinical-stage | Clinical assessment and global positioning |
| Autoimmune / CNS | Small molecule | Clinical-stage | Scientific evaluation and BD support |
| Immunology | Biologic | Clinical-stage | Asset assessment and partnering advisory |